TAK 128
Alternative Names: Y 128Latest Information Update: 24 Oct 2021
At a glance
- Originator Mitsubishi Pharma Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic neuropathies
Most Recent Events
- 02 Nov 2006 Discontinued - Phase-II for Diabetic neuropathies in Europe (unspecified route)
- 02 Nov 2006 Discontinued - Phase-II for Diabetic neuropathies in Japan (unspecified route)
- 02 Nov 2006 Discontinued - Phase-II for Diabetic neuropathies in USA (unspecified route)